What conditions does apotex's ruxolitinib treat?

What conditions does Apotex’s ruxolitinib treat?

Apotex markets ruxolitinib tablets in Canada under the brand name Jakavi. Jakavi (ruxolitinib) is used to treat specific blood cancers and a related inflammatory condition: [1]

- Myelofibrosis (including primary myelofibrosis and post–polycythemia vera or post–essential thrombocythemia myelofibrosis) [1]
- Polycythemia vera (in adults who have an inadequate response to or are unable to tolerate hydroxyurea) [1]
- Graft-versus-host disease (acute or chronic) when indicated based on the product’s approved use [1]

What else should you check on the prescription label?

Approved use can depend on the exact formulation/strength and on whether the condition is newly diagnosed versus previously treated. Checking the specific Jakavi product monograph and the strength you were prescribed can help confirm the intended indication. [1]

Are there age or prior-treatment limits?

Yes. For at least one key indication (polycythemia vera), use is limited to adults with inadequate response to, or inability to tolerate, hydroxyurea. [1]

Sources
[1] https://www.apotex.com/prescribing-information/jakavi